Mark Bernard, PhD

Mark Bernard, PhD has over 20 years of experience in the biotechnology and pharmaceutical industry. From 2001 to 2006, they worked as a Senior Research Scientist and Research Scientist at Targeted Molecules Corp., where they created Intellectual Property that resulted in the company being acquired and a $613M license agreement. From 2006 to 2007, they were a Principal Research Scientist at Bayer, where they led the Enzymology Group to advance hemophilia programs. From 2007 to 2012, they worked at Pfizer as a Principal Research Scientist, providing guidance and expertise for an oncology Antibody-Drug Conjugate therapeutic program and conducting research for novel inhibitors of human protein kinases. From 2012 to 2014, they worked at Harvard Medical School as an Instructor in Medicine (research faculty), where they conducted advanced research focusing on Human Immunodeficiency Virus, innate immunity, viral microRNAs, RNA interference and signaling. From 2014 to 2017, they worked as the Director of Enzymology at Omniome Inc., where they co-invented 3 US Patents for label-free Next-Generation Sequencing and achieved milestones that gained $8M in funding. Since 2017, they have been the President of Capienda Biotech, where they are the Principal Investigator for a National Science Foundation SBIR Phase I grant and is responsible for the company's advanced bioanalytical platform.

Mark Bernard, PhD has a diverse educational background. Mark received their Ph.D. in Biochemistry and Biophysics from Oregon State University. Following this, they were an Instructor in Medicine and Research Fellow at Harvard Medical School, where their research focused on HIV, innate immunity, viral microRNAs, RNA interference and signaling. From 1997 to 2000, they were a Postdoc at The University of Texas Health Science Center at Houston (UTHealth Houston), where they studied medical genetics and biology/biochemistry of novel tumor suppressors EXT1 and EXT2. Mark's educational background began with a B.S. in Biochemistry from University of California, Los Angeles.